Komori
Share Issuance and Disposal4575CanBas Co.,Ltd.Pharmaceuticals

Notice Regarding the Substantial Exercise of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Clause)

Of the 22nd Stock Acquisition Rights, 14,850 were exercised between 2 November 2026 and 20 November 2026, and 1,485,000 new shares were delivered. Of the total 20,000 issued rights, 5,150 remain unexercised.

Worth reading
72In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1485000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status of stock acquisition rights with exercise price adjustment clauses

発行・処分する株式数

1,485,000 new shares (2 November 2026 to 20 November 2026)

Terms of the stock acquisition rights
Exercise price
The exercise prices on each exercise date were ¥689, ¥669, ¥651, ¥614, ¥612, ¥633, ¥652, ¥664, ¥653, ¥648, ¥661, ¥634, ¥620 and ¥712. Details of the adjustment provisions are Not disclosed
Number of Stock Acquisition Rights
Total issued: 20,000 rights; exercised since the beginning of the month: 14,850 rights; currently unexercised: 5,150 rights
Most recent equity financing
Timing 30 October 2026 / Type Issuance of the 22nd Stock Acquisition Rights (with an exercise price adjustment provision) and the 23rd and 24th Stock Acquisition Rights (with an option to select the exercise price adjustment) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status of stock acquisition rights with exercise price adjustment clauses
Number of shares to be issued or disposed of1,485,000 new shares (2 November 2026 to 20 November 2026)
Total number of issued shares19,713,655 shares (as of the end of the month preceding the subject month, including 10,598 treasury shares) → Not disclosed
Exercise priceThe exercise prices on each exercise date were ¥689, ¥669, ¥651, ¥614, ¥612, ¥633, ¥652, ¥664, ¥653, ¥648, ¥661, ¥634, ¥620 and ¥712. Details of the adjustment provisions are Not disclosed
Number of Stock Acquisition RightsTotal issued: 20,000 rights; exercised since the beginning of the month: 14,850 rights; currently unexercised: 5,150 rights
Most recent equity financingTiming 30 October 2026 / Type Issuance of the 22nd Stock Acquisition Rights (with an exercise price adjustment provision) and the 23rd and 24th Stock Acquisition Rights (with an option to select the exercise price adjustment) / Amount Not disclosed
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the substantial exercise.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.